Peter Carmeliet
Peter Carmeliet
Peter Carmeliet (Dutch: [ˈpeːtər ˈkɑrməliːt]) is a Belgian physician and professor at the Katholieke Universiteit Leuven (Leuven, Belgium). He is also Adjunct Director of the VIB Department of Transgene Technology and Gene Therapy, KU Leuven. Among his research interests are vasculogenesis, angiogenesis, and vascular endothelial growth factor (VEGF).[1][2][3]
Awards
- 2002: Francqui Prize on Biological and Medical Sciences.
- 2005: Interbrew-Baillet Latour Health Prize, together with Désiré Collen.[4]
- 2010: Ernst Jung Prize in Medicine.[5]
References
- ↑ Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A, Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele, Nature 380, 435-439, 1996
- ↑ Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O’Shea KS, Powell-Braxton L, J. Hillan K, W. Moore M, Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene, Nature 380, 439-442, 1996
- ↑ Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons G, Van Rooijen N, Giacca M, Stassen J, Dewerchin M, Collen D, Carmeliet P, Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels, Cell 131, 463-75, 2007
- ↑ Bloom S., Belgian scientists awarded top honors, J Clin Invest. 2005 May;115(5):1106-7
- ↑ http://www.kuleuven.be/ci/28/ci28_carmeliet.html